Developments of Wild Type Oncolytic Viruses for Modifying the Antitumor Immune Response
DOI:
https://doi.org/10.58445/rars.1320Keywords:
Oncolytic Virus, Cancer, H-1Parvovirus, Measles, Reovirus, Newcastle Disease VirusAbstract
Oncolytic virotherapy shows promise as an anticancer agent with its field having grown considerably since its birth in the 20th century. Unfortunately, there are still many challenges that face oncolytic viruses (OV) that should be further studied to improve oncolytic viruses' potency. Challenges faced in the field of oncolytic virotherapy are: elucidating the factors in viral oncoselectivity, improving the clinical efficacy of OVs, reducing adverse events from OV treatment. A promising strategy that is currently being researched to improve OV treatment is combining OVs with another cancer therapeutic. A substantial barrier to the treatment of tumors is the immunosuppressive nature of the tumor microenvironment. Oncolytic viruses have demonstrated the ability to counteract this environment to boost immune response against tumors.
References
Pelner, L., Fowler, G. A. & Nauts, H. C. Effects of concurrent infections and their toxins on the course of leukemia. Acta Med. Scand. Suppl. 338, 1–47 (1958).
Cao, G.-D. et al. The Oncolytic Virus in Cancer Diagnosis and Treatment. Front. Oncol. 10, 1786 (2020).
Russell, S. J., Peng, K.-W. & Bell, J. C. Oncolytic virotherapy. Nat. Biotechnol. 30, 658–670 (2012).
Santos Apolonio, J. et al. Oncolytic virus therapy in cancer: A current review. World J Virol 10, 229–255 (2021).
Desjardins, A., Vlahovic, G. & Friedman, H. S. Vaccine Therapy, Oncolytic Viruses, and Gliomas. Oncology 30, 211–218 (2016).
Chen, C.-Y., Hutzen, B., Wedekind, M. F. & Cripe, T. P. Oncolytic virus and PD-1/PD-L1 blockade combination therapy. Oncolytic Virother 7, 65–77 (2018).
Uche, I. K., Kousoulas, K. G. & Rider, P. J. F. The Effect of Herpes Simplex Virus-Type-1 (HSV-1) Oncolytic Immunotherapy on the Tumor Microenvironment. Viruses 13, (2021).
Tan, E. W., Abd-Aziz, N., Poh, C. L. & Tan, K. O. Engineered Oncolytic Adenoviruses: An Emerging Approach for Cancer Therapy. Pathogens 11, (2022).
Cox, R. M. & Plemper, R. K. Structure and organization of paramyxovirus particles. Curr. Opin. Virol. 24, 105–114 (2017).
Wang, N. et al. CD150 is a member of a family of genes that encode glycoproteins on the surface of hematopoietic cells. Immunogenetics 53, 382–394 (2001).
Dörig, R. E., Marcil, A., Chopra, A. & Richardson, C. D. The human CD46 molecule is a receptor for measles virus (Edmonston strain). Cell 75, 295–305 (1993).
Rota, J. S., Wang, Z. D., Rota, P. A. & Bellini, W. J. Comparison of sequences of the H, F, and N coding genes of measles virus vaccine strains. Virus Res. 31, 317–330 (1994).
Galanis, E. et al. Phase I trial of intraperitoneal administration of an oncolytic measles virus strain engineered to express carcinoembryonic antigen for recurrent ovarian cancer. Cancer Res. 70, 875–882 (2010).
Cotmore, S. F. et al. The family Parvoviridae. Arch. Virol. 159, 1239–1247 (2014).
Bretscher, C. & Marchini, A. H-1 Parvovirus as a Cancer-Killing Agent: Past, Present, and Future. Viruses 11, (2019).
Angelova, A. L., Geletneky, K., Nüesch, J. P. F. & Rommelaere, J. Tumor Selectivity of Oncolytic Parvoviruses: From in vitro and Animal Models to Cancer Patients. Front Bioeng Biotechnol 3, 55 (2015).
Bär, S., Rommelaere, J. & Nüesch, J. P. F. PKCη/Rdx-driven phosphorylation of PDK1: a novel mechanism promoting cancer cell survival and permissiveness for parvovirus-induced lysis. PLoS Pathog. 11, e1004703 (2015).
Angelova, A. L. et al. Improvement of gemcitabine-based therapy of pancreatic carcinoma by means of oncolytic parvovirus H-1PV. Clin. Cancer Res. 15, 511–519 (2009).
Decaro, N. et al. Virological and molecular characterization of a mammalian orthoreovirus type 3 strain isolated from a dog in Italy. Vet. Microbiol. 109, 19–27 (2005).
Strong, J. E., Tang, D. & Lee, P. W. Evidence that the epidermal growth factor receptor on host cells confers reovirus infection efficiency. Virology 197, 405–411 (1993).
Gong, J., Sachdev, E., Mita, A. C. & Mita, M. M. Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity. World J Methodol 6, 25–42 (2016).
Forsyth, P. et al. A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol. Ther. 16, 627–632 (2008).
Gollamudi, R. et al. Intravenous administration of Reolysin, a live replication competent RNA virus is safe in patients with advanced solid tumors. Invest. New Drugs 28, 641–649 (2010).
Thirukkumaran, C. M. et al. Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic. Cancer Res. 70, 2435–2444 (2010).
Comins, C. et al. REO-10: a phase I study of intravenous reovirus and docetaxel in patients with advanced cancer. Clin. Cancer Res. 16, 5564–5572 (2010).
Ganar, K., Das, M., Sinha, S. & Kumar, S. Newcastle disease virus: current status and our understanding. Virus Res. 184, 71–81 (2014).
Biswas, M. et al. Cell-type-specific innate immune response to oncolytic Newcastle disease virus. Viral Immunol. 25, 268–276 (2012).
Dortmans, J. C. F. M., Koch, G., Rottier, P. J. M. & Peeters, B. P. H. Virulence of Newcastle disease virus: what is known so far? Vet. Res. 42, 122 (2011).
Liu, T. et al. Optimization of oncolytic effect of Newcastle disease virus Clone30 by selecting sensitive tumor host and constructing more oncolytic viruses. Gene Ther. 28, 697–717 (2021).
Hotte, S. J. et al. An optimized clinical regimen for the oncolytic virus PV701. Clin. Cancer Res. 13, 977–985 (2007).
Pecora, A. L. et al. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J. Clin. Oncol. 20, 2251–2266 (2002).
Laurie, S. A. et al. A phase 1 clinical study of intravenous administration of PV701, an oncolytic virus, using two-step desensitization. Clin. Cancer Res. 12, 2555–2562 (2006).
Pidelaserra-Martí, G. & Engeland, C. E. Mechanisms of measles virus oncolytic immunotherapy. Cytokine Growth Factor Rev. 56, 28–38 (2020).
Allaume, X. et al. Retargeting of rat parvovirus H-1PV to cancer cells through genetic engineering of the viral capsid. J. Virol. 86, 3452–3465 (2012).
Phillips, M. B. et al. Current understanding of reovirus oncolysis mechanisms. Oncolytic Virother 7, 53–63 (2018).
Song, H., Zhong, L.-P., He, J., Huang, Y. & Zhao, Y.-X. Application of Newcastle disease virus in the treatment of colorectal cancer. World J Clin Cases 7, 2143–2154 (2019).
Bashir, T., Horlein, R., Rommelaere, J. & Willwand, K. Cyclin A activates the DNA polymerase delta -dependent elongation machinery in vitro: A parvovirus DNA replication model. Proc. Natl. Acad. Sci. U. S. A. 97, 5522–5527 (2000).
Strong, J. E. & Lee, P. W. The v-erbB oncogene confers enhanced cellular susceptibility to reovirus infection. J. Virol. 70, 612–616 (1996).
Marcato, P., Shmulevitz, M., Pan, D., Stoltz, D. & Lee, P. W. Ras transformation mediates reovirus oncolysis by enhancing virus uncoating, particle infectivity, and apoptosis-dependent release. Mol. Ther. 15, 1522–1530 (2007).
Song, L., Ohnuma, T., Gelman, I. H. & Holland, J. F. Reovirus infection of cancer cells is not due to activated Ras pathway. Cancer Gene Ther. 16, 382 (2009).
Muñoz-Alía, M. Á. et al. MeV-Stealth: A CD46-specific oncolytic measles virus resistant to neutralization by measles-immune human serum. PLoS Pathog. 17, e1009283 (2021).
Clarke, J. L. et al. Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? Neuro. Oncol. 13, 1118–1124 (2011).
Sborov, D. W. et al. A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma. Clin. Cancer Res. 20, 5946–5955 (2014).
CTG Labs - NCBI. https://clinicaltrials.gov/study/NCT00408590?cond=peritoneal%20cancer&intr=measles%20virus&rank=1&tab=results.
Dispenzieri, A. et al. Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma. Leukemia 31, 2791–2798 (2017).
Hajda, J. et al. Phase 2 Trial of Oncolytic H-1 Parvovirus Therapy Shows Safety and Signs of Immune System Activation in Patients With Metastatic Pancreatic Ductal Adenocarcinoma. Clin. Cancer Res. 27, 5546–5556 (2021).
Gonzalez, H., Hagerling, C. & Werb, Z. Roles of the immune system in cancer: from tumor initiation to metastatic progression. Genes Dev. 32, 1267–1284 (2018).
Schirrmacher, V., van Gool, S. & Stuecker, W. Counteracting Immunosuppression in the Tumor Microenvironment by Oncolytic Newcastle Disease Virus and Cellular Immunotherapy. Int. J. Mol. Sci. 23, (2022).
Fearon, D. T. Immune-Suppressing Cellular Elements of the Tumor Microenvironment. Annu. Rev. Cancer Biol. 1, 241–255 (2017).
Russell, L., Peng, K. W., Russell, S. J. & Diaz, R. M. Oncolytic Viruses: Priming Time for Cancer Immunotherapy. BioDrugs 33, 485–501 (2019).
Stanford, M. M., Breitbach, C. J., Bell, J. C. & McFadden, G. Innate immunity, tumor microenvironment and oncolytic virus therapy: friends or foes? Curr. Opin. Mol. Ther. 10, 32–37 (2008).
Corrales, L., McWhirter, S. M., Dubensky, T. W., Jr & Gajewski, T. F. The host STING pathway at the interface of cancer and immunity. J. Clin. Invest. 126, 2404–2411 (2016).
Marchini, A., Daeffler, L., Pozdeev, V. I., Angelova, A. & Rommelaere, J. Immune Conversion of Tumor Microenvironment by Oncolytic Viruses: The Protoparvovirus H-1PV Case Study. Front. Immunol. 10, 1848 (2019).
Maeda, S. et al. Interferon-α acts on the S/G2/M phases to induce apoptosis in the G1 phase of an IFNAR2-expressing hepatocellular carcinoma cell line. J. Biol. Chem. 289, 23786–23795 (2014).
Mansour, M., Palese, P. & Zamarin, D. Oncolytic specificity of Newcastle disease virus is mediated by selectivity for apoptosis-resistant cells. J. Virol. 85, 6015–6023 (2011).
Paglino, J. C., Andres, W. & van den Pol, A. N. Autonomous parvoviruses neither stimulate nor are inhibited by the type I interferon response in human normal or cancer cells. J. Virol. 88, 4932–4942 (2014).
Folkman, J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1, 27–31 (1995).
Leung, D. W., Cachianes, G., Kuang, W. J., Goeddel, D. V. & Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246, 1306–1309 (1989).
Motz, G. T. & Coukos, G. The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat. Rev. Immunol. 11, 702–711 (2011).
Rintoul, J. L. et al. ORFV: a novel oncolytic and immune stimulating parapoxvirus therapeutic. Mol. Ther. 20, 1148–1157 (2012).
Ueda, N., Wise, L. M., Stacker, S. A., Fleming, S. B. & Mercer, A. A. Pseudocowpox virus Encodes a Homolog of Vascular Endothelial Growth Factor. Virology 305, 298–309 (2003).
Inder, M. K., Ueda, N., Mercer, A. A., Fleming, S. B. & Wise, L. M. Bovine papular stomatitis virus encodes a functionally distinct VEGF that binds both VEGFR-1 and VEGFR-2. J. Gen. Virol. 88, 781–791 (2007).
Arulanandam, R. et al. VEGF-Mediated Induction of PRD1-BF1/Blimp1 Expression Sensitizes Tumor Vasculature to Oncolytic Virus Infection. Cancer Cell 28, 210–224 (2015).
Breitbach, C. J. et al. Oncolytic vaccinia virus disrupts tumor-associated vasculature in humans. Cancer Res. 73, 1265–1275 (2013).
Su, Y., Su, C. & Qin, L. Current landscape and perspective of oncolytic viruses and their combination therapies. Transl. Oncol. 25, 101530 (2022).
Lichty, B. D., Breitbach, C. J., Stojdl, D. F. & Bell, J. C. Going viral with cancer immunotherapy. Nat. Rev. Cancer 14, 559–567 (2014).
Ribas, A. et al. Oncolytic Virotherapy Promotes Intratumoral T Cell Infiltration and Improves Anti-PD-1 Immunotherapy. Cell 170, 1109–1119.e10 (2017).
Rajani, K. et al. Combination Therapy With Reovirus and Anti-PD-1 Blockade Controls Tumor Growth Through Innate and Adaptive Immune Responses. Mol. Ther. 24, 166–174 (2016).
Mahalingam, D. et al. Pembrolizumab in Combination with the Oncolytic Virus Pelareorep and Chemotherapy in Patients with Advanced Pancreatic Adenocarcinoma: A Phase Ib Study. Clin. Cancer Res. 26, 71–81 (2020).
LaRocca, C. J. & Warner, S. G. Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials. Clin. Transl. Med. 7, 35 (2018).
Sei, S. et al. Synergistic antitumor activity of oncolytic reovirus and chemotherapeutic agents in non-small cell lung cancer cells. Mol. Cancer 8, 47 (2009).
Lolkema, M. P. et al. A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. Clin. Cancer Res. 17, 581–588 (2011).
Macedo, N., Miller, D. M., Haq, R. & Kaufman, H. L. Clinical landscape of oncolytic virus research in 2020. J Immunother Cancer 8, (2020).
Downloads
Posted
Categories
License
Copyright (c) 2024 Grant Murphy
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.